Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
150.56B
Market cap150.56B
Price-Earnings ratio
19.69
Price-Earnings ratio19.69
Dividend yield
6.42%
Dividend yield6.42%
Average volume
60.31M
Average volume60.31M
High today
$27.19
High today$27.19
Low today
$26.33
Low today$26.33
Open price
$26.76
Open price$26.76
Volume
72.65M
Volume72.65M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 150.56B, Pfizer(PFE) trades at $26.42. The stock has a price-to-earnings ratio of 19.69 and currently yields dividends of 6.4%.

During the trading session on 2026-02-05, Pfizer(PFE) shares reached a daily high of $27.19 and a low of $26.33. At a current price of $26.42, the stock is +0.3% higher than the low and still -2.8% under the high.

Trading volume for Pfizer(PFE) stock has reached 72.65M, versus its average volume of 60.31M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Nasdaq 2h
Pfizer Launches TrumpRx Program To Expand Affordable Access To Medicines Across U.S.

(RTTNews) - Pfizer Inc. (PFE) announced the launch of its TrumpRx program, designed to make innovative medicines more affordable and accessible to millions of A...

Pfizer Launches TrumpRx Program To Expand Affordable Access To Medicines Across U.S.
TipRanks 4h
Pfizer launches program on TrumpRx to make medicines ‘more affordable’

Pfizer (PFE) said it “announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Start...

MarketWatch 7h
TrumpRx’s launch is hours away. Here’s why it may not lower drug prices for most Americans.

President Donald Trump in September announced a drug-pricing deal with Pfizer. The Trump administration has since struck deals with 15 other pharmaceutical comp...

TrumpRx’s launch is hours away. Here’s why it may not lower drug prices for most Americans.

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

Nasdaq 8h
Pfizer Q2 2025 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Pfizer Q2 2025 Earnings Call Transcript
Nasdaq 11h
March 27th Options Now Available For Pfizer

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the March 27th expiration. At Stock Options Channel , our YieldBoost formula h...

March 27th Options Now Available For Pfizer
The Motley Fool 19h
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. Eli Lilly's (LLY +10.33%) obesity drug, Zepbound, generated sales of $13.5 billion i...

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
Simply Wall St 23h
Pfizer Obesity Trial Results Spark Questions On Valuation And Dividend Risk

Pfizer (NYSE:PFE) reported statistically significant weight loss results from its Phase 2b VESPER-3 trial for a monthly injectable GLP-1 obesity drug. The cand...

Pfizer Obesity Trial Results Spark Questions On Valuation And Dividend Risk
Nasdaq 1d
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026

Key Points Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up...

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
TipRanks 1d
Pfizer and BioNTech Pause modRNA Shingles Ambitions

Biontech Se Sponsored Adr (BNTX), Pfizer Inc (PFE) announced an update on their ongoing clinical study. modRNA shingles pursuit from Pfizer and BioNTech now ce...

Nasdaq 2d
Will the Market Crash in 2026? Here's What History Says and What to Do About It

Key Points There are fears that stocks are overvalued right now, and some data backs this up. This could lead to a market crash, though we can't be certain....

Will the Market Crash in 2026? Here's What History Says and What to Do About It

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.